HC Wainwright Issues Positive Outlook for Cybin Earnings

Cybin Inc. (NASDAQ:HELP) – Analysts at HC Wainwright upped their Q2 2027 EPS estimates for Cybin in a research note issued on Wednesday, August 19th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of ($0.67) for the quarter, up from their prior forecast of ($0.80). The consensus estimate for Cybin’s current full-year earnings is ($3.23) per share. HC Wainwright also issued estimates for Cybin’s Q3 2027 earnings at ($0.68) EPS, Q4 2027 earnings at ($0.59) EPS, FY2027 earnings at ($2.78) EPS, Q1 2028 earnings at ($0.59) EPS, Q2 2028 earnings at ($0.53) EPS, Q3 2028 earnings at ($0.53) EPS, Q4 2028 earnings at ($0.54) EPS, FY2028 earnings at ($2.19) EPS, FY2029 earnings at ($1.09) EPS, FY2030 earnings at $0.62 EPS and FY2031 earnings at $3.78 EPS.

HELP has been the subject of several other research reports. Wells Fargo & Company began coverage on Cybin in a research note on Monday, July 27th. They issued an “overweight” rating and a $16.00 price target for the company. TD Cowen raised their target price on shares of Cybin from $8.00 to $62.00 and gave the company a “buy” rating in a research note on Thursday. Five investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $48.60.

Cybin Price Performance

HELP opened at $12.47 on Friday. The stock’s 50 day moving average price is $7.66 and its 200 day moving average price is $6.20. The stock has a market cap of $911.06 million, a P/E ratio of -4.13 and a beta of 0.55. Cybin has a 12 month low of $3.76 and a 12 month high of $12.72.

Cybin (NASDAQ:HELP) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.11).

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Osaic Holdings Inc. increased its stake in Cybin by 46.7% in the 2nd quarter. Osaic Holdings Inc. now owns 7,543 shares of the company’s stock valued at $63,000 after buying an additional 2,400 shares during the period. Bank of America Corp DE boosted its stake in shares of Cybin by 66.8% during the 2nd quarter. Bank of America Corp DE now owns 29,443 shares of the company’s stock valued at $247,000 after buying an additional 11,790 shares during the period. Finally, Millennium Management LLC grew its holdings in shares of Cybin by 1,388.5% during the 4th quarter. Millennium Management LLC now owns 1,028,549 shares of the company’s stock valued at $8,414,000 after acquiring an additional 959,448 shares in the last quarter. 17.94% of the stock is owned by hedge funds and other institutional investors.

Key Cybin News

Here are the key news stories impacting Cybin this week:

• Positive Sentiment: TD Cowen raised its price target from $8 to $62 and assigned a “buy” rating, implying substantial potential upside from Cybin’s recent trading level. The aggressive target increase appears to be the primary catalyst behind investor interest. HELP Stock Jumps 6% After TD Cowen Hikes Target Nearly 8x To $62
• Positive Sentiment: HC Wainwright improved several longer-term earnings forecasts. Its FY2027 loss estimate narrowed to $2.78 per share from $2.96, while FY2029 losses narrowed to $1.09 from $1.20. The firm also raised projected profitable earnings for FY2030 to $0.62 from $0.36 and FY2031 to $3.78 from $3.23, suggesting greater confidence in Cybin’s eventual commercialization and profitability potential. Cybin Price Target Raised by TD Cowen
• Positive Sentiment: HC Wainwright also raised its Q2 2027 and Q3 2027 EPS forecasts to losses of $0.67 and $0.68, respectively, from $0.80 losses, and modestly improved its Q1 and Q4 2028 estimates.
• Neutral Sentiment: The updated forecasts still call for substantial losses in the near and medium term. The current full-year consensus remains a loss of $3.23 per share, and Cybin’s recent quarterly loss of $0.91 per share missed the $0.80 consensus estimate.
• Negative Sentiment: HC Wainwright lowered its FY2028 EPS forecast to a $2.19 loss from a $2.09 loss and reduced estimates for Q2, Q3 and Q4 2028. These revisions indicate that the path to profitability could take longer than previously expected.

Cybin Company Profile

Cybin Inc is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of mental health disorders. Headquartered in Toronto and listed on the NASDAQ under the symbol HELP, Cybin pursues research and development programs intended to harness the therapeutic potential of psychedelic compounds to address conditions with significant unmet need.

The company operates a drug discovery and development platform aimed at creating novel small-molecule psychedelic analogs and tailored formulations.